c-Met: A Promising Therapeutic Target in Bladder Cancer

被引：13
|
作者：
Feng, Yanfei [1 ]
Yang, Zitong [2 ]
Xu, Xin [2 ,3 ]
机构：
[1] Zhejiang Chinese Med Univ, Affiliated Coll 2, Hangzhou, Peoples R China
[2] Zhejiang Univ, Affiliated Hosp 1, Sch Med, Dept Urol, Hangzhou, Peoples R China
[3] Zhejiang Univ, Affiliated Hosp 1, Sch Med, Dept Urol, 79th Qingchun Rd, Hangzhou 310003, Peoples R China
来源：
CANCER MANAGEMENT AND RESEARCH | 2022年 / 14卷
基金：
中国国家自然科学基金;
关键词：
c; -Met; HGF; noncoding RNA; bladder cancer; review; HEPATOCYTE GROWTH-FACTOR; RECEPTOR TYROSINE KINASE; TRANSITIONAL-CELL CARCINOMA; UROTHELIAL CARCINOMA; URINARY-BLADDER; SCATTER FACTOR; PROGNOSTIC INDICATOR; LUNG ADENOCARCINOMA; EXPRESSION; MIGRATION;
D O I：
10.2147/CMAR.S369175
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Mesenchymal-epithelial transition factor (c-Met) belongs to the tyrosine kinase receptor family and is overexpressed in various human cancers. Its ligand is hepatocyte growth factor (HGF), and the HGF/c-Met signaling pathway is involved in a wide range of cellular processes, including cell proliferation, migration, and metastasis. Emerging studies have indicated that c-Met expression is strongly associated with bladder cancer (BCa) development and prognosis. Therefore, c-Met is a potential therapeutic target for BCa treatment. Recently, the aberrant expression of noncoding RNAs was found to play a significant role in tumour progression. There is a close connection between c-Met and noncoding RNA. Herein, we summarized the biological function and prognostic value of c-Met in BCa, as well as its potential role as a drug target. The relation of c-Met and ncRNA was also described in the paper.
引用
收藏
页码：2379 / 2388
页数：10
相关论文
共 50 条
  • [41] Identification of c-Met as a novel target of γ-glutamylcyclotransferase
    Saito, Yumiko
    Taniguchi, Keiko
    Ii, Hiromi
    Horinaka, Mano
    Kageyama, Susumu
    Nakata, Susumu
    Ukimura, Osamu
    Sakai, Toshiyuki
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [42] c-Met: A new target for nanoparticle therapeutics
    Harris, Alesha
    Phelps, Amanda
    Petros, Robby A.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2014, 247
  • [43] Identification of c-Met as a novel target of γ-glutamylcyclotransferase
    Yumiko Saito
    Keiko Taniguchi
    Hiromi Ii
    Mano Horinaka
    Susumu Kageyama
    Susumu Nakata
    Osamu Ukimura
    Toshiyuki Sakai
    Scientific Reports, 13
  • [44] The hepatocyte growth factor/c-Met signaling pathway as a therapeutic target to inhibit angiogenesis
    You, Weon-Kyoo
    McDonald, Donald M.
    BMB REPORTS, 2008, 41 (12) : 833 - 839
  • [45] Target proteins involved in resistance to c-Met inhibitors and their therapeutic role in human melanoma
    Fong, Jason T.
    Puri, Neelu
    CANCER RESEARCH, 2011, 71
  • [46] MET Gene Dysregulation as a Promising Therapeutic Target in Lung Cancer-A Review
    Terlecka, Paulina
    Krawczyk, Pawel
    Grenda, Anna
    Milanowski, Janusz
    JOURNAL OF PERSONALIZED MEDICINE, 2021, 11 (12):
  • [47] AXL in bladder cancer: A marker of invasion, metastasis and promising therapeutic target
    Dyer, J. E.
    Dormer, J.
    Heer, R.
    Robson, C.
    Tulchinsky, E.
    Mellon, J. K.
    BRITISH JOURNAL OF SURGERY, 2014, 101 : 57 - 57
  • [48] Discovery of novel dual c-Met/HDAC inhibitors as a promising strategy for cancer therapy
    Hu, Hao
    Chen, Fei
    Dong, Yuhong
    Liu, Yajing
    Gong, Ping
    BIOORGANIC CHEMISTRY, 2020, 101
  • [49] Signal transduction of c-met involved in bladder carcinogensis
    Liu, H
    MOLECULAR BIOLOGY OF THE CELL, 2002, 13 : 152A - 152A
  • [50] C-Met in Invasive Breast Cancer
    Ho-Yen, Colan M.
    Green, Andrew R.
    Rakha, Emad A.
    Brentnall, Adam R.
    Ellis, Ian O.
    Kermorgant, Stephanie
    Jones, J. L.
    CANCER, 2014, 120 (02) : 163 - 171
12345